CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients

BACKGROUND: The objective of the CHEOPS trial was to assess the benefit of adding aromatase inhibitor (AI) to metronomic chemotherapy, oral vinorelbine, 50 mg, three times a week for pre-treated, HR + /HER2- metastatic breast cancer patients. METHODS: In this multicentric phase II study, patients ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bailleux, Caroline, Arnaud, Antoine, Frenel, Jean-Sébastien, Chabaud, Sylvie, Bachelot, Thomas, You, Benoît, Stefani, Laëtitia, Tixidre, Claire Garnier, Simon, Hélène, Beal-Ardisson, Dominique, Jacquin, Jean-Philippe, Del Piano, Francesco, Lortholary, Alain, Cornea, Claudiu, Greilsamer, Charlotte, Largillier, Rémy, Brocard, Fabien, Legouffe, Eric, Atlassi, Mustapha, Hardy-Bessard, Anne-Claire, Heudel, Pierre-Etienne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950168/
https://www.ncbi.nlm.nih.gov/pubmed/36602669
http://dx.doi.org/10.1007/s12282-022-01426-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950168/
https://www.ncbi.nlm.nih.gov/pubmed/36602669
http://dx.doi.org/10.1007/s12282-022-01426-1

Ejemplares similares